SV News
16 March 2021Portfolio NewsAlchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease- 2 February 2021Portfolio NewsQurAlis Continues to Expand Leadership Team with Two Key Hires
6 January 2021Portfolio NewsRibometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics- 18 November 2020Portfolio NewsCaraway Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Further Investigate the Function of the Lysosomal Ion Channel TMEM175 and Gene Variants Linked to Parkinson’s Disease
16 November 2020Portfolio NewsCerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
12 November 2020Portfolio NewsNitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson- 28 September 2020Portfolio NewsQurAlis named as one of Fierce Biotech's 2020 Fierce 15
- 22 July 2020Portfolio NewsExcellent news today from our portfolio company @Cerevance on the expansion of its Series B financing round, adding a further $20 million to the $45 million announced in April.
- 1 July 2020Portfolio NewsQurAlis Announces Agreement to Strengthen ALS Pipeline
2 June 2020Portfolio NewsAstronauTx Announces an Alliance With Concept Life Sciences to Accelerate the Identification of Novel Therapies For Alzheimer's Disease
13 May 2020Portfolio NewsQurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)- 23 April 2020Portfolio NewsNitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases
